Link Between Erectile Dysfunction And Obesity Explored In Obesity And Weight Management Aug 26, 2009
The authors emphasize that "the complicated interplay of weight and other health conditions relate to common medical symptoms, such as ED. We are reminded that atherosclerosis can cause not only macrovascular disease such as heart attack and stroke, but also microvascular disease, of which ED is one example.". "If you are looking for another reason to lose weight, research now suggests that erectile dysfunction can improve with weight loss," says James O. Hill, PhD, Editor-in-Chief of Obesity... (Science Daily)
GSK: RECORD trial results do not change Avandias CV risk stigma, bone fracture risk, physicians say Jun 19, 2009
There is no clinical trial evidence that Avandia provides any beneficial effect on microvascular or macrovascular outcomes; hence, in the context of overall evidence, clinicians should not prescribe Avandia, because safer and cheaper alternatives are available to treat Type II diabetes, he said ... The bottom line is that physicians look for microvascular and macrovascular changes, he said. (FT.com -- Markets)
Effect of Strict Diabetes Control on Heart Still Unclear Jun 16, 2009
"Data related to macrovascular effects on the heart are less well understood or less conclusive.". Research presented last year on the ACCORD trial found that intensive lowering of blood sugar in people with poorly controlled type 2 diabetes did not have a significant effect on reducing cardiovascular events, such as heart attack and stroke. (MEDLINEplus)
Diabetes with Coronary Disease — A Moving Target amid Evolving Therapies? Jun 16, 2009
The adverse microvascular and macrovascular consequences of diabetes are well recognized, as is the accompanying accelerated rate of atherosclerosis that predisposes patients to coronary artery disease and to higher rates of myocardial infarction and death. Treatment strategies that are aimed at reducing these events have embraced both optimal medical therapy (lifestyle intervention, vigilant glycemic control, and aggressive secondary prevention) and interventional management (catheter-based and... (New England Journal of Medicine)
Drug May Lessen Amputation Risk for Diabetics May 23, 2009
"Classic markers of macrovascular and microvascular risk were associated with lower-extremity amputations in patients with type 2 diabetes," concluded Professor Anthony Keech, of the National Health and Medical Research Council Clinical Trials Centre at the University of Sydney, in Australia, and his colleagues. "These findings could lead to a change in standard treatment for the prevention of diabetes-related lower-limb amputations," they concluded, adding that the results "showed a reduction... (MEDLINEplus)
Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study Feb 27, 2009
These findings on macrovascular disease build on earlier results of the FIELD trial showing clear benefits for patients with microvascular complications ... The study evaluated whether treatment with fenofibrate (200 mg/day) for a median of 5 years could reduce macrovascular and microvascular complications of type 2 diabetes ... Macrovascular study endpoints were major coronary events (primary) and total cardiovascular events (secondary). (PR Newswire)
Experts Say Blood Sugar Guidelines Remain Effective Feb 7, 2009
However, less stringent AIC goals should be considered for diabetes patients with a "history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, and those with longstanding diabetes in whom the general goal is difficult to attain despite diabetes self-management education, appropriate glucose monitoring, and effective doses of multiple glucose lowering agents including insulin.". The recommendations were published... (MEDLINEplus)
New Criteria Could Expand Number of Liver Transplant Candidates Feb 7, 2009
The Milan criteria specifies that liver cancer patients with a single tumor of 5 centimeters or less in diameter, or three or fewer tumors, each no more than 3 cm in diameter and with no macrovascular invasion, can expect an excellent outcome after liver transplantation, with only a 10 percent risk of cancer recurrence. Survival of patients who don't meet the criteria is unpredictable, and there are no evidence-based guidelines to help doctors select patients who exceed the criteria but might... (MEDLINEplus)
